Opioid Management

Introduction to Opioid Therapy

Opioid therapy requires careful management to avoid withdrawal symptoms, with continuous scheduled dosing being more effective than as-needed dosing, according to the American College of Physicians 1
The American College of Physicians recommends verifying the current Suboxone dose with the prescriber to ensure adequate pain management, and reassuring patients that their addiction history will not prevent adequate pain management 1

Monitor patients for withdrawal symptoms, sedation, respiratory depression, and pain control, and adjust the dose based on these factors, as well as patient function and side effects 1, 2
Always screen for depression and other mental health conditions that may impact pain perception and management 2
The Clinical Opioid Withdrawal Scale (COWS) can be used to assess for withdrawal symptoms, and moderate to severe withdrawal symptoms (COWS score >12) may require reinstatement of Suboxone at the previous stable dose, stabilization for 1-2 weeks, and resumption of tapering with smaller increments and longer intervals between reductions, as suggested by clinical practice guidelines from the American Academy of Addiction Psychiatry 1

The typical dosing range for buprenorphine is 4-16 mg divided into 8-hour doses, and it can be titrated upward for improved analgesia 2
Buprenorphine is particularly beneficial for patients with a history of opioid use disorder who need pain management, as it has a long duration of action due to slow dissociation from receptors 2
The American College of Physicians recommends buprenorphine for patients with chronic noncancer pain requiring opioid therapy, due to its partial μ-opioid receptor agonist properties and high binding affinity 2
Consider dividing the buprenorphine dose to every 6-8 hours to maximize analgesic effect, and use conventional short-acting opioid analgesics at higher doses and shorter intervals, as recommended by the American College of Physicians 1

The target maintenance dose of methadone typically ranges from 60-120 mg daily, with divided doses may be needed initially for patients with rapid metabolism 1
Methadone may be preferred for patients with severe fentanyl dependence, those who have previously failed buprenorphine, or patients unable to tolerate even brief periods of withdrawal, while buprenorphine may be preferred for patients who can reliably follow the induction protocol or have concerns about methadone's side effects 1

For patients on buprenorphine therapy experiencing acute severe pain, continue the buprenorphine maintenance therapy and aggressively titrate short-acting opioid analgesics at higher doses and shorter intervals to overcome the partial blockade effect, as recommended by the American College of Physicians 1
Avoid mixed agonist-antagonist opioids (e.g., nalbuphine, butorphanol) as they may precipitate withdrawal, according to the American College of Physicians 1
A gradual tapering approach is recommended to minimize withdrawal symptoms, with dose reductions of approximately 25% every 1-2 weeks, and slower reductions at lower doses, although the exact protocol may vary depending on the patient's response and the clinical guidelines of organizations such as the American Society of Addiction Medicine 1

Buprenorphine is safer than morphine in patients with chronic kidney disease (stages 4-5), with no dose reduction necessary as it is primarily metabolized by the liver, according to the American Society of Nephrology 3
High BMI and high urine fentanyl concentration increase the risk of precipitated withdrawal, with adjusted odds ratios of 5.12 and 8.37, respectively 1
Fentanyl's lipophilicity can cause prolonged withdrawal onset, requiring longer wait times before buprenorphine induction, and patients transitioning from fentanyl may require higher doses of both medications due to fentanyl's high potency and the development of cross-tolerance 1

The American Academy of Pain Medicine suggests considering low-dose naltrexone as adjunctive therapy for mild-moderate neuropathic pain or inflammatory conditions, as it acts as an antagonist to toll-like receptor 4 linked to neuropathic pain and reduces pro-inflammatory cytokines 4
Low-dose naltrexone is often started at 1.5 mg at bedtime with gradual bi-weekly increases of 1.5 mg to maximum 4.5 mg, and is typically administered at bedtime to minimize side effects 4
The American College of Physicians recommends using non-opioid adjunctive therapies for withdrawal symptoms, including NSAIDs for pain and discomfort, clonidine for autonomic symptoms (0.1-0.2mg every 6 hours as needed), antiemetics for nausea/vomiting, and sleep aids for insomnia, as evidenced by a study published in 2006 1

The analgesic ratio for oral morphine to transdermal buprenorphine is approximately 75:1, with an example conversion being 60mg oral morphine ≈ 0.8mg/24h transdermal buprenorphine, as recommended by the American Society of Clinical Oncology 5
The Mayo Clinic recommends avoiding meperidine due to poor efficacy, multiple drug interactions, and toxicity risk, and advises against using QT-prolonging agents with buprenorphine due to contraindication 6